Type6 Therapeutics Inc. has disclosed cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and inflammatory disorders.

The researchers also provide clear evidence that CDK2 and CDK9 are inhibited in fadraciclib-treated cancer cells ... “The fadraciclib paper is the culmination of a productive collaboration of Cyclacel ...

Indirubin is the active ingredient of Danggui Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat chronic diseases. Here we identify indirubin and its analogues ...

day 1 and cycle 2, day 1 showed reductions in ctDNA. “Results from this study presented today at ESMO reinforce the idea that the novel and highly selective CDK2 inhibitor INCB123667 may provide ...

The study addresses the complex regulation of HSCs, highlighting p21's multifunctional nature beyond cell cycle control. Through the use of p21-tdTomato mice, researchers differentiate between p21 ...

Details of the presentation are listed below: About Cyclacel Pharmaceuticals, Inc.

Scientists at the Institute of Cancer Research, London, synthesised a prototype drug (CCT068127) that simultaneously targets two proteins called CDK2 and CDK9, in a collaboration with the company ...

Patients are preselected for CDKN2A and/or CDKN2B abnormalities -- Safety and efficacy data to be reported at an upcoming oncology medical ...

A life cycle is the series of stages something passes through during its lifetime. We also use the term for things that are not living, like cell phones. The life cycle for anything you buy includes ...

This new kind of mice, that count with most of the human immune cell types with lower ...

September 14, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with ...